New urinary biomarkers for diabetic kidney disease

Cheng Wang, CuiCui Li, WenYu Gong and Tanqi Lou*

Abstract

Diabetic kidney disease is the leading cause of end-stage renal disease in developed and developing countries. Microalbuminuria is the gold standard for detection and prediction of diabetic kidney disease and cardiovascular risk disease in clinical practice. However, microalbuminuria has several limitations, such as lower sensitivity, larger variability. It is urgent to explore higher sensitivity and specificity for earlier detection of diabetic kidney disease and more accurate prediction of the progression to end stage renal disease. We reviewed some new and important urinary biomarkers, such as: transferrin, immunoglobulin G, immunoglobulin M, Cystanic C, podocytes, type IV collagen, 8-oxo-7, 8-dihydro-2'-deoxyguanosine, ceruloplasmin, monocyte chemoattractant protein-1 and so on. We need good quality, long-term, large longitudinal trials to validate published biomarkers and find new biomarkers, considering biomarkers reviewed here are from small cross-sectional studies.

Keywords: Diabetic kidney disease, Biomarker, Urine

Diabetes mellitus (DM) is a chronic disease that affects 366 million people worldwide (6.4% of the adult population) and is expected to rise to 552 million by 2030 [1]. Diabetic kidney disease (DKD) is one of the most serious microvascular complications, which significantly impacts morbidity, mortality and quality of life. DKD occurs in approximately one-third of all people with diabetes and is the leading cause of renal failure in developed and developing countries. The first sign of DKD is considered to be microalbuminuria in clinical practice, while microalbuminuria has several limitations such as lower sensitive and larger variability. Therefore, earlier, more sensitive and specific biomarkers with greater predictability are needed. The aim of this review is to summarize new urinary biomarkers for glomerular injury associated with DKD.

Transferrin

Transferrin, a plasma protein, is very similar to albumin in weight. It is more readily filtered through glomerular barrier than albumin for being less anionic. Urinary transferrin is considered to be a more sensitive marker of glomerular damage in diabetic patients based on theory analysis and experimental results. Urinary transferrin excretion shows a good linear relationship with urinary albumin excretion in diabetic patients, and increased urinary transferrin excretion predicts the development of microalbuminuria in type 2 diabetic patients with normoalbuminuria [2]. A systemic review, including 13 studies, indicated that urinary transferrin excretion was a good marker for predicting onset of nephropathy [3]. However, urinary transferrin excretion is not specific for DKD because its elevation can be found in primary glomerulonephritis [4].

Immunoglobulin G

Immunoglobulin G (IgG) is a protein synthesized and secreted by plasma cells. It has a molecular weight of 150 kDa, which is larger than albumin. Urinary IgG excretion is higher in diabetic patients compared to healthy controls, and its excretion in diabetic patients with normoalbuminuria predicts the development of microalbuminuria [5]. Urinary IgG excretion correlates with the progression of glomerular diffuse lesions. One IgG isoform (IgG4) has been used more specifically as a marker of glomerular charge selectivity impairment. Only IgG4 excretion is elevated in patients with microalbuminuria, while the excretion of both IgG and IgG4 are increased in patients with macroalbuminuria compared with normoalbuminuric patients [6]. Recently, one study found that urinary concentration of
IgG2 in patients with normoalbuminuria was significantly higher than in healthy control, whereas further elevation of IgG2, IgG4, and IgA was more pronounced in patients with microalbuminuria. Fractional excretion of IgG2 was the highest among all immunoglobulins, which indicated that elevation of those particular immunoglobulin subtypes was a contribution of novel mechanisms in early DKD, different from charge and size barrier impairment [7]. One systemic review, including 13 studies, indicated urinary IgG was a good marker for predicting onset of nephropathy [3].

**Immunoglobulin M**

Immunoglobulin M (IgM), secreted by plasma cells, is the largest antibody in the human. Due to its large molecular radius, the appearance of IgM in urine indicates that a large, nonselctive pore exists in the glomerular capillary wall. One study showed that urine excretion of IgM was significantly higher in type 2 DM compared to type 1 DM, and patients with type 2 DM with nephrosclerosis had significantly higher urine excretion of IgM compared to the age-matched healthy subjects [8]. Another study found renal survival of type 2 diabetic patients was inversely associated with urine IgM excretion, which indicated that higher urinary IgM excretion was a better predictor of decline in kidney function than albuminuria in type 2 DM. However, urinary IgM excretion has not been regarded as an early marker of DKD, since its excretion in urine is associated with severe injury of the glomerular capillary wall, while it is also a promising marker which may predict the eventual need for renal replacement therapy [9].

**Cystatin C**

Cystatin C, a cysteine protease inhibitor, is a novel biomarker of renal damage. Serum Cystatin c is a good marker for assessing renal injuries, while urinary cystatin c was considered as a useful marker for the detection of DKD. One study from Zucker diabetic fatty (ZDF) rats indicated that urinary cystatin C was increased in ZDF rats where renal damage was not observed by histopathological assessment, and its levels in urine increased with the progression of renal damage, demonstrating the usefulness of early detection and accurate assessment of DKD [10]. Another study from type 2 diabetic patients found that urinary cystatin C increased with increasing degree of albuminuria and reached higher levels in macroalbuminuric patients. Urinary cystatin C levels were identified as an independent factor associated with estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m² in patients with normoalbuminuria, which indicated urinary cystatin C levels could be a useful marker for renal dysfunction in type 2 diabetic patients with normoalbuminuria [11].

**Podocytes**

Podocytes are key structural elements of the glomerular filtration barrier. It is accepted that podocytes’ injuries play an essential role in the progression of DKD [12]. Monitoring urine podocytes and podocyte-specific proteins can reveal potentially interesting urinary markers for the early diagnosis of DKD [13]. Podocytes in urine can be found in diabetic patients with micro- and macroalbuminuria [14]. Another study indicated that nephrinuria was found to be present in 100% of diabetic patients with micro- and macroalbuminuria, as well as 54% of patients with normoalbuminuria; what’s more, nephrinuria also correlated positively with albuminuria, which suggested that nephrinuria might be a biomarker of early DKD [15]. Urinary podocalyxin was higher in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage, which indicated that urinary podocalyxin might be a useful biomarker for detecting early podocyte injury in diabetic patients [16]. Another study found that urinary mRNA profiles of synaptopodin, podocyalxin, α-actin-4, and podocin were increased with the progression of DKD, which suggested that quantification of podocyte-associated molecules in urine will be a useful biomarker of DKD [17].

**Type IV Collagen**

Type IV collagen is the main constituent of both glomerular and tubular basement membranes as well as mesangial matrix. Urinary type IV collagen was significantly increased in both normoalbuminuric and microalbuminuric patients of type 2 DM compared with healthy controls, and urinary type IV collagen significantly correlated with the amount of albuminuria [18]. Another study found that urinary type IV collagen was more sensitive than albuminuria to detect renal damage in type 2 diabetic patients. A follow-up study showed that 25% of normoalbuminuric patients with increased urinary type IV collagen excretion developed microalbuminuria, while patients who stayed normoalbuminuria had a significant decrease in urinary type IV collagen excretion, which suggested that urinary type IV collagen is a marker to detect the progression of DKD [19,20].

**8-oxo-7, 8-dihydro-2’-deoxyguanosine**

It is well known that increased oxidative stress in diabetes contributes to the progression of diabetes and its complications. 8-oxo-7, 8-dihydro-2’-deoxyguanosine (8-oxodG), a marker of intracellular oxidative stress, can be assessed non-invasively in urine. Patients with higher excretion of 8-oxodG in urine compared with those patients with moderate or lower excretion of 8-oxodG showed significant progression of diabetic nephropathy, which indicates that 8-oxodG in urine is
a useful clinical marker to predict the development of diabetic nephropathy [21,22].

**Ceruloplasmin**

Ceruloplasmin (molecular weight = 151 kD) is the major copper-carrying protein in blood and more negatively charged than albumin, which makes it difficult to be filtered by the glomerulus. Urinary ceruloplasmin was found in normoalbuminuric diabetic patients, and its increase in urine had a predictive value for development of microalbuminuria in normoalbuminuric diabetic patients [23,24]. The ceruloplasmin/creatinine ratio is higher in DKD compared with non-diabetic patients, and its ratio has a sensitivity of 90-91%, specificity of 61–66% in diagnosing DKD [25]. All these data suggest that urinary ceruloplasmin is a promising marker of DKD, while further studies are needed to characterize its value compared to albuminuria, especially in type 1 diabetics, since all the studies have been done in type 2 diabetics.

**Monocyte chemoattractant protein-1 (MCP-1)**

Chemokines have been implicated in the pathogenesis of DKD, therefore, measurement of cytokine in urine might help to diagnosis DKD. Urinary MCP-1/creatinine in patients with macroalbuminuria was significantly higher than patients with normoalbuminuria and microalbuminuria, and urinary MCP-1 correlated with the rate of eGFR decline [26]. Another study found that urinary MCP-1 was significantly higher in patients presenting doubling of serum creatinine or death, and its levels were positively associated with the risk of doubling of serum creatinine or death after Cox regression; what’s more, urinary MCP-1 remained as significant independent predictors of doubling of serum creatinine or death [27]. All these data suggested that urinary MCP-1 might be a prognostic marker for progression of diabetic nephropathy, while more studies are needed to investigate whether urinary MCP-1 has a role in the setting of normoalbuminuria and microalbuminuria in DKD.

**Neutrophil gelatinase-associated lipocalin**

Neutrophil gelatinase-associated lipocalin (NGAL) has been evaluated in several studies of diabetic subjects. In one study, urine NGAL was 5–10-fold higher in normo- or microalbuminuric patients compared with healthy controls. Another study from short-term type 2 DM patients indicated urinary NGAL showed a negative correlation with eGFR, which suggested urinary NGAL might be a promising early marker for monitoring renal impairment in short-term T2DM patients [28]. Study from type 1 DM indicated that urine NGAL levels correlated with albumin/creatinine, and patients with higher albuminuria had higher urine NGAL levels, which suggested that elevated urinary NGAL values might indicate kidney damage [29].

**Identification of urinary markers by proteomic approaches**

Proteomics is a method aimed at discovering and identifying the complete set of proteins present in a given biological sample at a given time. Using a variant of two dimensional gel electrophoresis, they found urine samples from type 2 DM patients with microalbuminuria showed four main proteins accompanying with albumin: alpha-2 glycoprotein, alpha-1 acid glycoprotein, alpha-1 microglobulin and IgG [30]. Otu found a 12-peak proteomic signature in the baseline urine of type 2 DM patients who subsequently developed DKD [31]. The reported accuracy (71% sensitivity and 76% specificity) is encouraging in view of a future diagnostic assay. Zürbig used capillary electrophoresis-coupled mass spectrometry to profile the low-molecular weight proteome in urine samples from a longitudinal cohort of type 1 and 2 diabetic patients. They found collagen fragments were prominent biomarkers before onset of macroalbuminuria, and there is a decrease in collagen fragments before albumin excretion starts to increase [32]. Urinary proteomics enables noninvasive assessment of DN risk at an early stage, while more studies are needed to investigate the role of urinary proteomics in diabetic kidney disease.

**Novel biomarkers**

Recently, a study from uni-nephrectomized diabetic rats indicated urinary osteopontin, heart-type fatty acid binding protein appeared before the classical biomarkers of diabetic nephropathy, such as albuminuria and urinary protein excretion [33]. Study of males with Type 2 diabetes indicated human zinc-α (2) -glycoprotein might be a novel urinary biomarker for non-albuminuric diabetic nephropathy [34]. Another study suggested urinary mRNA levels of α-smooth muscle actin, fibronectin and matrix metalloproteinase-9 might be novel biomarkers of diabetic kidney disease [35]. McKittrick reported that urinary matrix metalloproteinase activity might be a sensitive, noninvasive, and clinically useful biomarker for predicting vascular remodeling in diabetic renal and vascular complications [36]. The above mentioned results are from small patient population and from animal experiments, which lead to limited use for clinical practice. We need larger perspective studies to confirm the utility of these biomarkers in diabetic kidney disease.

**Conclusion and future directions**

The current gold standard for detection and prediction of DKD is microalbuminuria; however, it has several limitations, such as lower sensitive and larger variability. It is urgent to explore higher sensitivity and specificity for earlier detection of DKD and more accurate prediction of the progression to end stage renal disease. Despite numbers of new biomarkers described, most studies are limited by either their small sample size or their cross-
sectional nature. We need large, prospective, multicenter trials enlisting both Type 1 and Type II diabetic patients with and without nephropathy for at least two decades to indently their role in clinical practice.

Abbreviations
DM: Diabetes mellitus; DKD: Diabetic kidney disease; IgG: Immunoglobulin G; IgM: Immunoglobulin M; KGR: Estimated glomerular filtration rate; 8-oxoG: 8-oxo-7, 8-dihydro-2′-deoxyguanosine; MCP-1: Monocyte chemoattractant protein-1; NGAL: Neutrophil gelatinase-associated lipocalin.

Competing interest
We declare that we have no competing interests.

Authors’ contributions
The review was designed by CW and TQL. CCL and WYG prepared some papers. The review was written by CW and TQL, edited by all authors, who have approved the final version.

Acknowledgement
The authors thank Dr Lian Zhao for assistance with the English version of the manuscript.

References
1. International Diabetes Federation: Diabetes Atlas Fifth Edition, International Diabetes Federation. Belgium: Brussels; 2011.
2. Zhou Y, Zhang X, Wu J: Diabetes Atlas Fifth Edition, International Diabetes Federation. Belgium: Brussels; 2011.
3. Hellermans ME, Kerschbaum J, Bakker SJ, et al. Validation of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med 2012, 29:567–577.
4. Mackinnon B, Shakeri L, Deighan CJ, et al: Urinary transferrin, high molecular weight proteinuria and the progression of renal disease. Clin Nephrol 2003, 59:252–258.
5. Nair T, Hosoba M, Kakei M, et al. Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29:142–144.
6. Bangstad HJ, Kafoid-Enevoldsen A, Dahl-Jorgensen K, et al: Glomerular charge selectivity and the influence of improved blood glucose control in Type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992, 35:165–1169.
7. Gehda T, Walker WH, Wolkow P, et al: Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes. Am J Physiol Renal Physiol 2012, 303F157–F162.
8. Bakouch D, Tencer J, Tapia J, et al: Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy. Kidney Int 2002, 61:203–208.
9. Tofik R, Toffert O, Rippe B, Bakouch D: Increased urinary IgM excretion predicts cardiovascular events in patients with type 1 diabetes nephropathy. BMC Med 2009, 4:39–40.
10. Ogah Y, Miyamoto Y: Urinary cystatin C as a biomarker for diabetic nephropathy and its immunochistochromatic localization in kidney in Zucker diabetic fatty (ZDF) rats. Exp Toxicol Pathol 2012, 11 [Epub ahead of print].
11. Jeon YK, Kim MR, Huh JE, et al: Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011, 26:258–263.
12. Wei L, Lembly KV, Yee B, et al: Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol 2011, 33:121–24.
13. Dalla Vesta M, Masiero A, Roiter AM, et al: Urinary podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003, 52:1031–1035.
14. Nakamura T, Ushiyama C, Suzuki S, et al: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379–1383.
15. Jim B, Ghanta M, Qipo A, et al: Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One 2012, 7:e30641.
16. Harada Y, Yamagata K, Tomino Y, et al: Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 2012, 52:2913–2919.
17. Zheng M, Lu LL, Ni J, et al: Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 2011, 6:e20431.
18. Shanmuganar P, Chan SP: Urinary type IV collagen levels in diabetes mellitus. Malay J Pathol 2010, 32:43–47.
19. Itojima N, Kimura T, Kanda T, et al: Type IV collagen as an early marker for diabetic nephropathy in non-insulin dependent diabetes mellitus. J Diabetes Complications 2000, 14:13–17.
20. Iijima T, Suzuki S, Sekizuka K, et al: Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998, 12:378–382.
21. Hinokio Y, Suzuki S, Hiei M, et al: Urinary excretion of 8-oxo-7,8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002, 45:877–882.
22. Broedbaek K, Weimann A, Stovgaard ES, et al: Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011, 51:1473–1479.
23. Narita T, Hosoba M, Kakei M, et al. Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29:142–4.
24. Narita T, Sasaki H, Hosoba M, et al: Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and osmorcoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004, 27:1176–1181.
25. Qin L-X, Zeng X, Huang G, et al: Changes in serum and urine ceruloplasmin concentrations in type 2 diabetes. Zhejiang da xue xue bao 2004, 29:208–211.
26. Tam FW, Riser BL, Meenan K, et al: Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CTGF) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009, 47:37–42.
27. Titan SM, Vieira JM Jr, Domínguez WW, et al: Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabetes Complications 2012, 26:546–553. doi:10.1016/j.jdiacomp.
28. Jain S, Rajput A, Kumar Y, et al: Proteomic analysis of urine protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005, 53:513–520.
29. Otu HH, Can H, Spentzos D, et al: Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30:538–543.
30. Ziniag F, Jerums G, Havird P, et al: Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes 2012, 61:S304–313 [Epub ahead of print].
31. Fu WJ, Xiong SL, Fang YG, et al: Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012, 41:82–88.
32. Demiri K, Abaci A, Kürme T, et al: Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents. J Pediatr Endocrinol Metab 2012, 25:517–523.
33. Alter ML, Krtschmer A, Von W, et al: Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 2012, 58:659–671.
34. Lim SC, Lijing DQ, Toy WC, et al: Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabet Med 2012, 29:495–499.
35. Zheng M, Lu LL, Cao YH, et al: Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Clin Endocrinol 2012, 76:657–664.
36. McCorristick J, Bogaert Y, Nadeau K, et al: Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol 2011, 301:F1326–F1333.

Cite this article as: Wang et al.: New urinary biomarkers for diabetic kidney disease. Biomarker Research 2013 1:9.